Next Article in Journal
Distal Colon Motor Dysfunction in Mice with Chronic Kidney Disease: Putative Role of Uremic Toxins
Next Article in Special Issue
Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience
Previous Article in Journal
Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessArticle
Toxins 2018, 10(5), 203; https://doi.org/10.3390/toxins10050203

Botulinum Toxin Type A Injection for Cervical Dystonia in Adults with Dyskinetic Cerebral Palsy

1
Department of Rehabilitation Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Korea
2
Department of Rehabilitation Medicine, Incheon St. Mary’s Hospital, Incheon 22711, Korea
*
Author to whom correspondence should be addressed.
Received: 9 April 2018 / Revised: 4 May 2018 / Accepted: 15 May 2018 / Published: 16 May 2018
(This article belongs to the Special Issue Botulinum Toxin Treatment of Movement Disorders)
View Full-Text   |   Download PDF [1173 KB, uploaded 16 May 2018]   |  

Abstract

We aimed to evaluate the efficacy and safety of injecting botulinum toxin A (BoNT-A) into the neck muscles to treat cervical dystonia (CD) in patients with dyskinetic cerebral palsy (CP). This was a randomized, double-blinded, placebo-controlled trial with cross-over design. We prospectively enrolled adults with dyskinetic CP who were over 20 years old and had been clinically diagnosed with CD for more than one year. The primary outcome measure was the change in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) at four weeks from the baseline TWSTRS. Seventeen patients were initially enrolled, but one patient was excluded after the final evaluation because of a violation of the study protocol. At four weeks, the BoNT-A injections showed significant improvement in TWSTRS total scores compared to the saline injections (p = 0.0286 for ANCOVA). At 12 weeks, the BoNT-A injections resulted in greater improvements in TWSTRS total scores than the saline injections without statistical significance (p = 0.0783 for ANCOVA). Dysphagia occurred in three out of 16 patients: two after BoNT-A and one after saline. The dysphagia was transient and improved naturally within two weeks without any special treatment. BoNT-A injection for CD in adults with dyskinetic CP is relatively safe and improves pain and disability. View Full-Text
Keywords: clinical trials randomized controlled; cervical dystonia; botulinum toxin; dyskinetic cerebral palsy clinical trials randomized controlled; cervical dystonia; botulinum toxin; dyskinetic cerebral palsy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Yi, Y.G.; Kim, K.; Yi, Y.; Choi, Y.-A.; Leigh, J.-H.; Bang, M.S. Botulinum Toxin Type A Injection for Cervical Dystonia in Adults with Dyskinetic Cerebral Palsy. Toxins 2018, 10, 203.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top